CORRESPONDENCE

Reply to: “Rethinking Treatment Priorities in Estrogen Receptor–Low Breast Cancer” and “CDK4/6 Inhibitors in Estrogen Receptor–Low Breast Cancer”

Goetz, Matthew P. MD^{^,}
Choong, Grace M. MD
Hoskin, Tanya L. MS
Boughey, Judy C. MD
Wijayawardana, Sameera R. PhD
Ingle, James N. MD

Matthew P. Goetz, MD and Grace M. Choong, MD, Department of Oncology, Mayo Clinic, Rochester, MN; Tanya L. Hoskin, MS, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN; Judy C. Boughey, MD, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN; Sameera R. Wijayawardana, PhD, Eli Lilly and Company, Indianapolis, IN; and James N. Ingle, MD, Department of Oncology, Mayo Clinic, Rochester, MN

Corresponding author: Matthew P. Goetz, MD; e-mail: [email protected].

Journal of Clinical Oncology, August 28, 2025. | DOI: 10.1200/JCO-25-01688

Copyright © 2025 by American Society of Clinical Oncology